Apatinib can inhibit tumor cell growth by blocking the VEGFR2/STAT3/Bcl-2 or Akt/GSK3β/angiogenin signaling pathways, suppressing tumor angiogenesis in osteosarcoma and anaplastic thyroid cancer, respectively [14, 15]. Here, KDR is linked to neoplasm.